Mary F Brunette

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2736628/publications.pdf

Version: 2024-02-01

91 4,146 papers citations

31 60 h-index g-index

99 99
all docs docs citations

99 times ranked 5136 citing authors

#	Article	IF	CITATIONS
1	Relapse prevention through health technology program reduces hospitalization in schizophrenia. Psychological Medicine, 2023, 53, 4114-4120.	4.5	3
2	Integrated vs nonintegrated treatment for perinatal opioid use disorder: retrospective cohort study. American Journal of Obstetrics & Synecology MFM, 2022, 4, 100489.	2.6	18
3	Tobacco Product Use and Functionally Important Respiratory Symptoms Among US Adolescents/Young Adults. Academic Pediatrics, 2022, 22, 1006-1016.	2.0	8
4	Treatment Interruptions and Telemedicine Utilization in Serious Mental Illness: Retrospective Longitudinal Claims Analysis. JMIR Mental Health, 2022, 9, e33092.	3.3	13
5	E-Cigarette Provision to Promote Switching in Cigarette Smokers With Serious Mental Illness—A Randomized Trial. Nicotine and Tobacco Research, 2022, 24, 1405-1412.	2.6	5
6	Tobacco Use and Respiratory Symptoms Among Adults: Findings From the Longitudinal Population Assessment of Tobacco and Health (PATH) Study 2014–2016. Nicotine and Tobacco Research, 2022, 24, 1607-1618.	2.6	13
7	Usability and Acceptability of Two Smartphone Apps for Smoking Cessation Among Young Adults With Serious Mental Illness: Mixed Methods Study. JMIR Mental Health, 2021, 8, e26873.	3.3	10
8	Workshop on Implementation Science and Digital Therapeutics for Behavioral Health. JMIR Mental Health, 2021, 8, e17662.	3.3	15
9	Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review. Psychiatric Services, 2021, 72, 429-436.	2.0	45
	Review. 1 Sychilatric Services, 2021, 72, 125 150.		
10	In Memory of Alan I. Green. Journal of Dual Diagnosis, 2021, 17, 99-100.	1.2	1
10		2.6	7
	In Memory of Alan I. Green. Journal of Dual Diagnosis, 2021, 17, 99-100. Acceptability and Usability of Mobile Apps for Smoking Cessation Among Young Adults With Psychotic		
11	In Memory of Alan I. Green. Journal of Dual Diagnosis, 2021, 17, 99-100. Acceptability and Usability of Mobile Apps for Smoking Cessation Among Young Adults With Psychotic Disorders and Other Serious Mental Illness. Frontiers in Psychiatry, 2021, 12, 656538. Implementation of collaborative care for depressive disorder treatment among accountable care	2.6	7
11 12	In Memory of Alan I. Green. Journal of Dual Diagnosis, 2021, 17, 99-100. Acceptability and Usability of Mobile Apps for Smoking Cessation Among Young Adults With Psychotic Disorders and Other Serious Mental Illness. Frontiers in Psychiatry, 2021, 12, 656538. Implementation of collaborative care for depressive disorder treatment among accountable care organizations. Medicine (United States), 2021, 100, e26539. The Impact of THC and CBD in Schizophrenia: A Systematic Review. Frontiers in Psychiatry, 2021, 12,	2.6	4
11 12 13	In Memory of Alan I. Green. Journal of Dual Diagnosis, 2021, 17, 99-100. Acceptability and Usability of Mobile Apps for Smoking Cessation Among Young Adults With Psychotic Disorders and Other Serious Mental Illness. Frontiers in Psychiatry, 2021, 12, 656538. Implementation of collaborative care for depressive disorder treatment among accountable care organizations. Medicine (United States), 2021, 100, e26539. The Impact of THC and CBD in Schizophrenia: A Systematic Review. Frontiers in Psychiatry, 2021, 12, 694394. Validation of an Index for Functionally Important Respiratory Symptoms among Adults in the Nationally Representative Population Assessment of Tobacco and Health Study, 2014âe"2016.	2.6 1.0 2.6	7 4 34
11 12 13	In Memory of Alan I. Green. Journal of Dual Diagnosis, 2021, 17, 99-100. Acceptability and Usability of Mobile Apps for Smoking Cessation Among Young Adults With Psychotic Disorders and Other Serious Mental Illness. Frontiers in Psychiatry, 2021, 12, 656538. Implementation of collaborative care for depressive disorder treatment among accountable care organizations. Medicine (United States), 2021, 100, e26539. The Impact of THC and CBD in Schizophrenia: A Systematic Review. Frontiers in Psychiatry, 2021, 12, 694394. Validation of an Index for Functionally Important Respiratory Symptoms among Adults in the Nationally Representative Population Assessment of Tobacco and Health Study, 2014–2016. International Journal of Environmental Research and Public Health, 2021, 18, 9688.	2.6 1.0 2.6	7 4 34 6
11 12 13 14	In Memory of Alan I. Green. Journal of Dual Diagnosis, 2021, 17, 99-100. Acceptability and Usability of Mobile Apps for Smoking Cessation Among Young Adults With Psychotic Disorders and Other Serious Mental Illness. Frontiers in Psychiatry, 2021, 12, 656538. Implementation of collaborative care for depressive disorder treatment among accountable care organizations. Medicine (United States), 2021, 100, e26539. The Impact of THC and CBD in Schizophrenia: A Systematic Review. Frontiers in Psychiatry, 2021, 12, 694394. Validation of an Index for Functionally Important Respiratory Symptoms among Adults in the Nationally Representative Population Assessment of Tobacco and Health Study, 2014–2016. International Journal of Environmental Research and Public Health, 2021, 18, 9688. Schizophrenia Spectrum and Other Psychotic Disorders., 2021,	2.6 1.0 2.6 2.6	7 4 34 6

#	Article	IF	CITATIONS
19	Perceptions of Mobile Apps for Smoking Cessation Among Young People in Community Mental Health Care: Qualitative Study. JMIR Formative Research, 2020, 4, e19860.	1.4	12
20	Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder. Journal of Clinical Psychiatry, 2020, 81, .	2.2	17
21	Gabapentin Enacarbil Extendedâ€Release for Alcohol Use Disorder: A Randomized, Doubleâ€Blind, Placeboâ€Controlled, Multisite Trial Assessing Efficacy and Safety. Alcoholism: Clinical and Experimental Research, 2019, 43, 158-169.	2.4	60
22	Implementation and fidelity assessment of the NAVIGATE treatment program for first episode psychosis in a multi-site study. Schizophrenia Research, 2019, 204, 271-281.	2.0	31
23	Pilot study of a mobile smoking cessation intervention for low-income smokers with serious mental illness. Journal of Smoking Cessation, 2019, 14, 203-210.	1.0	7
24	Adolescents' Use of Digital Technologies and Preferences for Mobile Health Coaching in Public Mental Health Settings. Frontiers in Public Health, 2019, 7, 178.	2.7	53
25	Sequential and simultaneous treatment approaches to cannabis use disorder and tobacco use. Journal of Substance Abuse Treatment, 2019, 98, 39-46.	2.8	11
26	Potent Dopamine D2 Antagonists Block the Reward-Enhancing Effects of Nicotine in Smokers With Schizophrenia. Schizophrenia Bulletin, 2019, 45, 1300-1308.	4.3	12
27	Use of Smartphones, Computers and Social Media Among People with SMI: Opportunity for Intervention. Community Mental Health Journal, 2019, 55, 973-978.	2.0	53
28	Electronic Cigarette Use During a Randomized Trial of Interventions for Smoking Cessation Among Medicaid Beneficiaries with Mental Illness. Journal of Dual Diagnosis, 2019, 15, 184-191.	1.2	11
29	Incentivizing healthy lifestyle behaviors to reduce cardiovascular risk in people with serious mental illness: An equipoise randomized controlled trial of the wellness incentives program. Contemporary Clinical Trials, 2019, 81, 1-10.	1.8	4
30	Off-hours use of a smartphone intervention to extend support for individuals with schizophrenia spectrum disorders recently discharged from a psychiatric hospital. Schizophrenia Research, 2019, 206, 200-208.	2.0	24
31	Attitudes about smoking cessation treatment, intention to quit, and cessation treatment utilization among young adult smokers with severe mental illnesses. Addictive Behaviors, 2019, 89, 248-255.	3.0	16
32	Menthol cigarette use in young adult smokers with severe mental illnesses. Nicotine and Tobacco Research, 2019, 21, 691-694.	2.6	7
33	Alcohol Use Disorder and Schizophrenia and Schizoaffective� Disorders. Alcohol Research: Current Reviews, 2019, 40, .	3.6	42
34	Flavour capsule cigarette use among US adult cigarette smokers. Tobacco Control, 2018, 27, 650-655.	3.2	33
35	Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis. JAMA Psychiatry, 2018, 75, 555.	11.0	516
36	Demographic and clinical correlates of substance use disorders in first episode psychosis. Schizophrenia Research, 2018, 194, 4-12.	2.0	65

#	Article	IF	CITATIONS
37	Brief Web-Based Interventions for Young Adult Smokers With Severe Mental Illnesses: A Randomized, Controlled Pilot Study. Nicotine and Tobacco Research, 2018, 20, 1206-1214.	2.6	25
38	Randomized Trial of Interventions for Smoking Cessation Among Medicaid Beneficiaries With Mental Illness. Psychiatric Services, 2018, 69, 274-280.	2.0	28
39	Mental Health Problems and Onset of Tobacco Use Among 12- to 24-Year-Olds in the PATH Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2018, 57, 944-954.e4.	0.5	51
40	Important Questions About the Impact of Medical Marijuana on People With Serious Mental Illness. Psychiatric Services, 2018, 69, 1181-1183.	2.0	0
41	Use of Academic Detailing With Audit and Feedback to Improve Antipsychotic Pharmacotherapy. Psychiatric Services, 2018, 69, 1021-1028.	2.0	6
42	Longitudinal associations between youth tobacco and substance use in waves 1 and 2 of the Population Assessment of Tobacco and Health (PATH) Study. Drug and Alcohol Dependence, 2018, 191, 25-36.	3.2	45
43	Impact of comprehensive treatment for first episode psychosis on substance use outcomes: A randomized controlled trial. Psychiatry Research, 2018, 268, 303-311.	3.3	44
44	Monitoring of Patients on Second-Generation Antipsychotics: A National Survey of Child Psychiatrists. Psychiatric Services, 2017, 68, 958-961.	2.0	17
45	Systematic review of social media interventions for smoking cessation. Addictive Behaviors, 2017, 73, 81-93.	3.0	144
46	An Online Survey of Family Members' Beliefs and Attitudes About Smoking and Mental Illness. Journal of Dual Diagnosis, 2017, 13, 179-183.	1.2	5
47	Improving Cardiometabolic Monitoring of Children on Antipsychotics. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 916-919.	1.3	15
48	Preferences for Smoking Cessation Support from Family and Friends Among Adults with Serious Mental Illness. Psychiatric Quarterly, 2017, 88, 701-710.	2.1	17
49	Mobile Phone Apps for Smoking Cessation: Quality and Usability Among Smokers With Psychosis. JMIR Human Factors, 2017, 4, e7.	2.0	36
50	Harnessing Facebook for Smoking Reduction and Cessation Interventions: Facebook User Engagement and Social Support Predict Smoking Reduction. Journal of Medical Internet Research, 2017, 19, e168.	4.3	65
51	Mobile Mindfulness Intervention on an Acute Psychiatric Unit: Feasibility and Acceptability Study. JMIR Mental Health, 2017, 4, e34.	3.3	45
52	Characteristics and Predictors of Intention to use Cessation Treatment among Smokers with Schizophrenia: Young Adults Compared to Older Adults. Journal of Substance Abuse and Alcoholism, 2017, 5, .	2.0	6
53	Appeal of electronic cigarettes in smokers with serious mental illness. Addictive Behaviors, 2016, 59, 30-34.	3.0	58
54	Health Technology Intervention After Hospitalization for Schizophrenia: Service Utilization and User Satisfaction. Psychiatric Services, 2016, 67, 1035-1038.	2.0	23

#	Article	IF	CITATIONS
55	Abstinence and Use of Community-Based Cessation Treatment After a Motivational Intervention Among smokers with Severe Mental Illness. Community Mental Health Journal, 2016, 52, 446-456.	2.0	10
56	Development and usability testing of a web-based smoking cessation treatment for smokers with schizophrenia. Internet Interventions, 2016, 4, 113-119.	2.7	22
57	An open-label pilot study of quetiapine plus mirtazapine for heavy drinkers with alcohol use disorder. Alcohol, 2016, 53, 45-50.	1.7	12
58	Coordinated Technology-Delivered Treatment to Prevent Rehospitalization in Schizophrenia: A Novel Model of Care. Psychiatric Services, 2016, 67, 444-447.	2.0	22
59	Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program. American Journal of Psychiatry, 2016, 173, 362-372.	7.2	601
60	mHealth for Schizophrenia: Patient Engagement With a Mobile Phone Intervention Following Hospital Discharge. JMIR Mental Health, 2016, 3, e34.	3.3	117
61	A pre-post pilot study of a brief, web-based intervention to engage disadvantaged smokers into cessation treatment. Addiction Science & Elinical Practice, 2015, 10, 3.	2.6	22
62	Expanding Cessation Pharmacotherapy Via Videoconference Educational Outreach to Prescribers. Nicotine and Tobacco Research, 2015, 17, 960-967.	2.6	12
63	Treating Tobacco Use Disorder in Pregnant Women in Medication-Assisted Treatment for an Opioid Use Disorder: A Systematic Review. Journal of Substance Abuse Treatment, 2015, 52, 40-47.	2.8	48
64	Duration of Untreated Psychosis in Community Treatment Settings in the United States. Psychiatric Services, 2015, 66, 753-756.	2.0	100
65	Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders. JAMA Psychiatry, 2014, 71, 1350.	11.0	318
66	Impaired functional connectivity of brain reward circuitry in patients with schizophrenia and cannabis use disorder: Effects of cannabis and THC. Schizophrenia Research, 2014, 158, 176-182.	2.0	55
67	Carbon monoxide feedback in a motivational decision support system for nicotine dependence among smokers with severe mental illnesses. Journal of Substance Abuse Treatment, 2013, 45, 319-324.	2.8	16
68	Do smoking cessation websites meet the needs of smokers with severe mental illnesses?. Health Education Research, 2012, 27, 183-190.	1.9	42
69	Smoking and Quitting Beliefs, Attitudes, and Behaviors Among Smokers With Severe Mental Illness From Three Race/Ethnicity Groups. Journal of Dual Diagnosis, 2012, 8, 180-187.	1.2	15
70	Do Symptoms and Cognitive Problems Affect the Use and Efficacy of a Web-Based Decision Support System for Smokers With Serious Mental Illness?. Journal of Dual Diagnosis, 2012, 8, 315-325.	1.2	16
71	An Electronic Decision Support System to Motivate People With Severe Mental Illnesses to Quit Smoking. Psychiatric Services, 2011, 62, 360-366.	2.0	52
72	Developing a quit smoking website that is usable by people with severe mental illnesses Psychiatric Rehabilitation Journal, 2011, 35, 111-116.	1.1	44

#	Article	IF	Citations
73	A Randomized Trial of Clozapine Versus Other Antipsychotics for Cannabis Use Disorder in Patients With Schizophrenia. Journal of Dual Diagnosis, 2011, 7, 50-63.	1.2	41
74	Public-Academic Partnerships: A Program to Improve the Quality of Antipsychotic Prescribing in a Community Mental Health System. Psychiatric Services, $2011,62,1004-6$.	2.0	4
75	Dextromethorphan Abuse and Dependence in Adolescents. Journal of Dual Diagnosis, 2010, 6, 266-278.	1.2	8
76	A qualitative study of how individuals with severe mental illness assess smoking risks. Mental Health and Substance Use: Dual Diagnosis, 2010, 3, 110-123.	0.5	13
77	An open label study of quetiapine in patients with schizophrenia and alcohol disorders. Mental Health and Substance Use: Dual Diagnosis, 2009, 2, 203-211.	0.5	7
78	Clozapine, Olanzapine, or Typical Antipsychotics for Alcohol Use Disorder in Patients With Schizophrenia. Journal of Dual Diagnosis, 2008, 4, 344-354.	1.2	6
79	Implementation of Integrated Dual Disorders Treatment: A Qualitative Analysis of Facilitators and Barriers. Psychiatric Services, 2008, 59, 989-995.	2.0	97
80	Psychosocial interventions for the long-term management of patients with severe mental illness and co-occurring substance use disorder. Journal of Clinical Psychiatry, 2006, 67 Suppl 7, 10-7.	2.2	12
81	Clozapine Use and Relapses of Substance Use Disorder Among Patients With Co-occurring Schizophrenia and Substance Use Disorders. Schizophrenia Bulletin, 2005, 32, 637-643.	4.3	98
82	Psychosocial Interventions for Adults with Severe Mental Illnesses and Co-Occurring Substance Use Disorders. Journal of Dual Diagnosis, 2005, 1, 57-82.	1.2	56
83	Pharmacologic Treatments for Co-Occurring Substance Use Disorders in Patients with Schizophrenia. Journal of Dual Diagnosis, 2005, 1, 41-55.	1.2	9
84	A review of research on residential programs for people with severe mental illness and coâ€occurring substance use disorders. Drug and Alcohol Review, 2004, 23, 471-481.	2.1	167
85	Integrated Family Treatment for Parents with Severe Psychiatric Disabilities Psychiatric Rehabilitation Journal, 2004, 28, 177-180.	1.1	13
86	Benzodiazepine Use and Abuse Among Patients With Severe Mental Illness and Co-occurring Substance Use Disorders. Psychiatric Services, 2003, 54, 1395-1401.	2.0	110
87	Community mental health care for women with severe mental illness who are parents. Community Mental Health Journal, 2002, 38, 153-165.	2.0	40
88	A Comparison of Long-Term and Short-Term Residential Treatment Programs for Dual Diagnosis Patients. Psychiatric Services, 2001, 52, 526-528.	2.0	68
89	HIV-related services for persons with severe mental illness: Policy and practice in new hampshire community mental health. Journal of Behavioral Health Services and Research, 2000, 27, 347-353.	1.4	13
90	HIV Risk Factors Among People With Severe Mental Illness in Urban and Rural Areas. Psychiatric Services, 1999, 50, 556-558.	2.0	20

#	Article	IF	CITATIONS
91	Health status of young adults with serious mental illness enrolled in integrated care. Microbial Biotechnology, 0, , .	1.7	1